A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02340611 |
Recruitment Status :
Completed
First Posted : January 16, 2015
Last Update Posted : June 12, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer | Drug: Olaparib Drug: Cediranib | Phase 2 |
Cediranib works by blocking (inhibiting) several specific proteins in cancer cells called the vascular endothelial growth factor (VEGF) receptors. These proteins are important in the formation of blood vessels to the tumor. It is believed that many tumors survive because the blood vessels on the tumors bring oxygen and nutrients to the cancer cells which enable them to grow. If the formation of the blood vessels is blocked, the tumor cells may die.
Olaparib works by blocking protein called poly [adenosine diphosphate-ribose] polymerase (PARP). PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA, molecules that contain important instructions for the development of cells). Many cancers are though develop from damaged DNA. By blocking PARP from fixing damaged DNA, the tumor cells may die.
Adding cediranib to olaparib, and therefore blocking several different mechanisms for cancer growth, may stop tumor growth.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 4 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer |
Study Start Date : | June 2015 |
Actual Primary Completion Date : | June 2018 |
Actual Study Completion Date : | June 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Cediranib and Olaparib
Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
|
Drug: Olaparib
Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
Other Names:
Drug: Cediranib Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
Other Names:
|
- Percentage of patients whose cancer shrinks or disappears after treatment [ Time Frame: 2 years ]
- Percentage of decrease in CA-125 levels after treatment [ Time Frame: 2 years ]
- Mutation status of genes compared to response to treatment [ Time Frame: 2 years ]
- Number of occurences per side effect and severity [ Time Frame: 2 years ]
- Assess patient reported outcomes during treatment [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18 years or older
- Performance status 2 or less
- Ovarian cancer, high grade serous or high grade endometrioid histology subtype
- Radiographically documented disease progression per RECIST 1.1
- Progression on olaparib therapy after an initial good response (more than 6 months)
- Patients must have adequate bone marrow, renal and hepatic function per local laboratory reference range
- Ongoing prior toxicities related to previous treatments recovered to grade 2 or less
- LVEF>50% by echocardiograms or MUGA
- Urine dipstick for proteinuria <2+
- Willing to undergo tumour biopsy pre-treatment
- Life expectancy of greater than 3 months
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Current bowel obstruction
- Known brain metastases
- Mean QTc >470 msec (with Bazett's correction) in screening ECG or history of familial long QT syndrome.
- Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- A New York Heart Association classification of III or IV requiring concurrent use of drugs or biologics with proarrhythmic potential.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or cediranib
- Unable to swallow orally administered medication and/or gastrointestinal disorders likely to interfere with absorption of the study medication.
- Myelodysplastic syndrome/acute myeloid leukaemia
- Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e.,hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02340611
Canada, Ontario | |
Princess Margaret Cancer Centre | |
Toronto, Ontario, Canada, M5G 2M9 |
Principal Investigator: | Amit Oza, M.D. | Princess Margaret Cancer Centre |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT02340611 |
Other Study ID Numbers: |
e-Volve |
First Posted: | January 16, 2015 Key Record Dates |
Last Update Posted: | June 12, 2018 |
Last Verified: | June 2018 |
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms |
Genital Diseases Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Olaparib Cediranib Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Protein Kinase Inhibitors |